Moderna

Lipid nanoparticle mRNA vaccine
#Arcturus #BioNTech #Covid-19 vaccine #Moderna #mRNA #mRNA-based vaccines

The companies taking the lead on mRNA

DDW’s Diana Spencer takes a closer look at three companies hoping to be the first to bring new mRNA therapeutics to the market. Although the concept of using mRNA to make therapeutics or vaccines has been around for decades, it took the urgency of a global pandemic for it to… Read More

#Exclusive Content

Lipid nanoparticle mRNA vaccine
#Advanced Therapies #Cell and gene therapy #Moderna #mRNA #Phase II trial #Rare disease

Positive initial data on first mRNA therapy for propionic acidemia

Moderna has reported encouraging interim data from its Phase I/II trial of mRNA-3927, an mRNA therapy for rare metabolic disorder propionic acidemia (PA). The data was presented at the 2023 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The ongoing global Phase… Read More

#News #Trending News

#Cancer immunotherapy #Immunology / Virology & Vaccines #Moderna #mRNA #mRNA-based vaccines #Tumour biology

Vaccine for the ‘previously undruggable’ just a decade away 

In an exclusive interview with The Guardian, Moderna said that cancer and heart disease vaccines would be ready by 20301. The pharmaceutical firm also provided promising updates on mRNA-4157/V940, which targets different tumour types, at Moderna’s Vaccines Day on 24 March 20232.   The… Read More

#News

UK
#Association of the British Pharmaceutical Industry #Immunology / Virology & Vaccines #Moderna #mRNA #Pharmaceuticals #Therapeutics

Moderna joins the Association of the British Pharmaceutical Industry 

Moderna has become the newest member of the UK’s pharmaceutical industry body, the Association of the British Pharmaceutical Industry (ABPI), building on the long-term commitment by the American-based company to expand its footprint and investment in the UK.  Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics… Read More

#News

Vaccine production
#BioNTech #Cancer immunotherapy #Cancer research #Clinical trials #Immunotherapy #Moderna #mRNA #mRNA-based vaccines #Personalised medicine #UK government

New UK partnership to accelerate mRNA research

It is hoped that a new partnership between the UK government and BioNTech will help accelerate clinical trials of personalised immunotherapies for cancer and infectious disease vaccines.  The agreement means cancer patients will get early access to trials exploring personalised mRNA therapies, like cancer vaccines.  Professor Uğur Şahin, Chief Executive… Read More

#Business & Investment #Cancer Research #News #Trending News

#Cancer research #Immunology / Virology & Vaccines #Melanoma #Merck #Moderna #mRNA #mRNA-based vaccines

mRNA cancer vaccine meets primary efficacy endpoint

Personalised mRNA vaccine mRNA-4157/V940 has demonstrated a clinically meaningful improvement in patients with late-stage melanoma.  The vaccine, in combination with Keytruda, met its primary endpoint of recurrence-free survival (RFS) for the adjuvant treatment of patients with stage III/IV melanoma following complete resection.  Adjuvant treatment with… Read More

#Cancer Research #News

RNA vaccine
#Cancer research #Cancer vaccine #Immuno-oncology #Immunology / Virology & Vaccines #Melanoma #Merck #Moderna #mRNA

Merck and Moderna to develop personalised cancer vaccine

Merck (MSD) and Moderna have revealed plans to work together on the development and commercialisation of an investigational personalised cancer vaccine. The companies will report data from the ongoing Phase II trial of mRNA-4157/V940 in combination with KEYTRUDA in high-risk melanoma later this year. “We have been collaborating with Merck… Read More

#Cancer Research #News #Trending News

#BioNTech #Covid-19 #Moderna #Pfizer

Moderna sues Pfizer/BioNTech over Covid patent

Biotechnology company Moderna has filed a patent infringement lawsuit against Pfizer and BioNTech in relation to the use of its messenger RNA (mRNA) technology and Pfizer and BioNTech’s Covid-19 Comirnaty vaccine. The lawsuits, which were made in the United States and Germany, state that Pfizer and BioNTech’s Covid-19 vaccine Comirnaty… Read More

#Covid-19 #News

#Covid-19 #Moderna

MHRA approves Moderna’s bivalent Covid booster  

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved an updated version of Moderna’s Covid-19 booster vaccine that targets two coronavirus variants.  Moderna’s ‘Spikevax’ booster dose targets the original coronavirus strain as well as the Omicron variant. Known as a bivalent vaccine, Spikevax was approved following… Read More

#Covid-19 #News

#Biopharma #Market reporting #Moderna #Pfizer #Pharma

What drove the top bio/pharma companies’ growth in 2021? 

The top 20 global innovative bio/pharma companies* reported a 24.9% growth in aggregate market capitalisation (MCAP)—from $2.8 trillion on 31 December 2020 to $3.4 trillion as of 31 December 2021, according to GlobalData.   The data and analytics company notes that a positive year-on-year MCAP growth was reported for 14 of… Read More

#News #Trending News #Trends & Analysis

#Covid-19 #FDA #Immunology / Virology & Vaccines #Moderna

Moderna receives full FDA approval for Covid-19 vaccine Spikevax 

The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Moderna’s Spikevax, an mRNA vaccine for prevention of Covid-19 in individuals 18 years of age and older.  Official comments   “Our Covid-19 vaccine has been administered to hundreds of millions of… Read More

#News

#Covid booster #Covid variants #Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA #Omicron

Moderna begins Omicron booster trial and presents durability data 

Moderna has dosed the first participant in a Phase II study of the company’s Omicron-specific booster candidate (mRNA-1273.529). Additionally, Moderna announced the publication of neutralising antibody data against the Omicron variant six months following a booster dose in The New England Journal of Medicine.   The mRNA-1273.529 trial  This extension… Read More

#News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA

Moderna announces strategy to address Omicron SARS-CoV-2 variant 

Moderna has announced updates to its strategy to address SARS-CoV-2 variants of concern, given the emergence of the B.1.1.529 (Omicron) variant.   What is Omicron?  The recently described Omicron variant includes mutations seen in the Delta variant that are believed to increase transmissibility and mutations seen… Read More

#Covid-19 #News #Trending News